2. Signaling Pathways
  3. Antibody-drug Conjugate/ADC Related
  4. Drug-Linker Conjugates for ADC

Drug-Linker Conjugates for ADC

ADC-Related Custom Services

Drug-Linker Conjugates for ADC

Related Products

PDF 0.45 MB

Drug-Linker Conjugates for Antibody Drug Conjugates (ADCs) comprise of an active cytotoxic drug and an appropriate linker. After linked to a monoclonal antibody, those conjugates can be used for making ADCs, which are targeted agents for cancer cells with high selectivity and cytotoxicity.

The drug units in drug-linker conjugates are cytotoxic agents (i.e. ADC cytotoxins or payloads) with antitumor activity and can be classified in DNA damaging agents and tubulin inhibitors. The most commonly used DNA damaging agents in ADCs are Duocarmycins, Pyrrolobenzodiazepines, Camptothecins and Daunorubicins/Doxorubicins, while the popular tubulin inhibitors are Auristatins and Maytansinoids. Besides, there are also many traditional cytotoxic agents can be used in ADCs.

ADC linkers currently undergoing clinical evaluation are mostly classified into two categories: cleavable and noncleavable. Cleavable linkers rely on processes inside the cell to liberate the toxin, and noncleavable linkers require proteolytic degradation of the antibody portion of the ADC for release of the cytotoxic molecule.

Drug-Linker Conjugates for ADC Isoform Specific Products:

Drug-Linker Conjugates for ADC Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-164837
    VcMMAE-Eribulin
    VcMMAE-Eribulin is a Drug-Linker Conjugates for ADC, which is composed of a linker and a toxic molecule MMAE (HY-15162) (Microtubule inhibitor) and Eribulin (HY-13442) (Microtubule inhibitor). VcMMAE-Eribulin can be used for ADC synthesis.
    VcMMAE-Eribulin
  • HY-128871
    VCP-Eribulin
    VCP-Eribulin consists the ADCs linker (VCP) and Eribulin. Eribulin is a mechanistically unique microtubule inhibitor for cancer. VCP-Eribulin is an Eribulin-based agent for antibody conjugates.
    VCP-Eribulin
  • HY-112806
    ST8155AA1
    ST8155AA1 is a part of antibody agent conjugates (ADCs) charged with HDAC inhibitor by a linker, shows antitumor activity.
    ST8155AA1
  • HY-145663
    HS-(CH2)3CO-L-Ala-D-Ala-L-Ala-NH-CH2-S-(CH2)5-CO-DM
    HS-(CH2)3CO-L-Ala-D-Ala-L-Ala-NH-CH2-S-(CH2)5-CO-DM is a agent-linker (peptide-cleavable) conjugate for ADC. DM indicates the maytansinoid moiety.
    HS-(CH2)3CO-L-Ala-D-Ala-L-Ala-NH-CH2-S-(CH2)5-CO-DM
  • HY-141662
    2',3'-cGAMP-C2-PPA
    2’,3’-cGAMP-C2-PPA is a cyclic dinucleotide interferon gene-stimulating protein (STING) agonist. 2’,3’-cGAMP-C2-PPA is a drug conjugated conjugate used to target antibody-drug conjugated conjugate (ADC) for the treatment of cancer. 2’,3’-cGAMP-C2-PPA can be used in the study of immune and tumor-related diseases.
    2',3'-cGAMP-C2-PPA
  • HY-128896
    Nitro-PDS-Tubulysin M
    Nitro-PDS-Tubulysin M is a synthetic ADC drug-linker conjugate composed of the tubulin polymerization inhibitor Tubulysin M (an ADC Cytotoxin) and Nitro-PDS (an ADC linker).
    Nitro-PDS-Tubulysin M
  • HY-128954
    Sulfo-PDBA-DM4
    Sulfo-PDBA-DM4 is a agent-linker conjugate composed of a potent a tubulin inhibitor DM4 and a linker Sulfo-PDBA to make antibody agent conjugate (ADC). Sulfo-PDBA is a gluthatione cleavable linker.
    Sulfo-PDBA-DM4
  • HY-128893
    MC-Sq-Cit-PAB-Gefitinib
    MC-Sq-Cit-PAB-Gefitinib is a agent-linker conjugate for ADC with potent antitumor activity by using Gefitinib (an EGFR tyrosine kinase inhibitor), linked via the ADC linker MC-Sq-Cit-PAB.
    MC-Sq-Cit-PAB-Gefitinib
  • HY-126692
    Mal-VC-PAB-ABAEP-Azonafide
    Mal-VC-PAB-ABAEP-Azonafide is a agent-linker conjugate for ADC with with potent antitumor activity by using Azonafide (a cytotoxin), linked via the ADC linker Mal-VC-PAB.
    Mal-VC-PAB-ABAEP-Azonafide
  • HY-128905
    MC-Val-Cit-PAB-dimethylDNA31
    		99.97%
    MC-Val-Cit-PAB-dimethylDNA31 is a agent-linker conjugate for ADC with potent antitumor activity by using dimethylDNA31, linked via the ADC linker MC-Val-Cit-PAB. DimethylDNA31 has effective bactericidal activity against persisters and stationary-phase S. aureus.
    MC-Val-Cit-PAB-dimethylDNA31
  • HY-101909
    Val-Cit-PAB-MMAF
    Val-Cit-PAB-MMAF is a agent-linker conjugate for ADC. Val-Cit-PAB-MMAF contains the ADCs linker (peptide Val-Cit-PAB) and a potent tubulin polymerization inhibitor MMAF (HY-15579)
    Val-Cit-PAB-MMAF
  • HY-163487
    Puxitatug samrotecan drug-linker
    Puxitatug samrotecan drug-linker (AZD8205 drug-linker) is part of the anti-B7-H4 antibody-conjugated active molecule ADC (drug-linker conjugate for ADC). Puxitatug samrotecan drug-linker contains a degradable ADC linker and a topoisomerase I inhibitor Exatecan (HY-13631).
    Puxitatug samrotecan drug-linker
  • HY-148380
    Mal-PEG8-Phe-Lys-PAB-Exatecan
    Mal-PEG8-Phe-Lys-PAB-Exatecan (compound 15) is a agent-linker conjugate for ADC, composed of degradable linker Mal-PEG8-Phe-Lys-PAB and toxin molecule Exatecan (HY-13631) composition.
    Mal-PEG8-Phe-Lys-PAB-Exatecan
  • HY-15578G
    McMMAF (GMP)
    McMMAF GMP is a GMP grade McMMAF (HY-15578). McMMAF is a protective group (maleimidocaproyl)-conjugated MMAF, which is a potent tubulin polymerization inhibitor. McMMAF can be used as a agent-linker for antibody-drug conjugates (ADC). McMMAF is uncleavable, and must be internalized and degraded within a cell, releasing cysteine-McMMAF as the active agent.
    McMMAF (GMP)
  • HY-145736A
    β-Glucuronide-dPBD-PEG5-NH2 TFA
    β-Glucuronide-dPBD-PEG5-NH2 TFA is the β-glucuronide-linked pyrrolobenzodiazepine dimer, which binds to the prenylated antibody for synthesis of antibody-drug conjugate (ADC) cIRCR201-dPBD.β-glucuronide-linkage as a cleavable linker. β-Glucuronide-dPBD-PEG5-NH2 TFA, as a proagent of cIRCR201-dPBD, reduces side effects. β-Glucuronide-dPBD-PEG5-NH2 TFA can induce apoptosis and arrest cell cycle. β-Glucuronide-dPBD-PEG5-NH2 TFA has antitumor activity.
    β-Glucuronide-dPBD-PEG5-NH2 TFA
  • HY-145736
    β-Glucuronide-dPBD-PEG5-NH2
    β-Glucuronide-dPBD-PEG5-NH2 is the β-glucuronide-linked pyrrolobenzodiazepine dimer, which binds to the prenylated antibody for synthesis of antibody-drug conjugate (ADC) cIRCR201-dPBD. β-glucuronide-linkage as a cleavable linker. β-Glucuronide-dPBD-PEG5-NH2, as a proagent of cIRCR201-dPBD, reduces side effects. β-Glucuronide-dPBD-PEG5-NH2 can induce apoptosis and arrest cell cycle. β-Glucuronide-dPBD-PEG5-NH2 has antitumor activity.
    β-Glucuronide-dPBD-PEG5-NH2
  • HY-148812
    Gly-Mal-Gly-Gly-Phe-Gly-amide-methylcyclopropane-Exatecan
    Gly-Mal-Gly-Gly-Phe-Gly-amide-methylcyclopropane-Exatecan is used for ADC Synthesis.
    Gly-Mal-Gly-Gly-Phe-Gly-amide-methylcyclopropane-Exatecan
  • HY-148668A
    MC-Gly-Gly-Phe-Gly-(S)-Cyclopropane-Exatecan
    MC-Gly-Gly-Phe-Gly-(R)-Cyclopropane-Exatecan is a agent-linker conjugates for ADC, consisting Exatecan (HY-13631). Exatecan is a DNA Topoisomerase I inhibitor (IC50=2.2 μM).
    MC-Gly-Gly-Phe-Gly-(S)-Cyclopropane-Exatecan
  • HY-174279
    MCC-AAQ-Exa
    MCC-AAQ-Exa is a drug-linker conjugates for ADC, obtained by condensing the linker with Exatecan (HY-13631) and can be used to prepare antibody-drug conjugates (ADCs). MCC is an ADC linker containing a maleimide fragment.
    MCC-AAQ-Exa
  • HY-164310
    TCO-PEG3-Glu-Val-Cit-PABC-MMAF
    TCO-PEG3-Glu-Val-Cit-PABC-MMAF is a linker-drug conjugate, which is consisted of a click pair TCO, a spacer PEG, a cleavable linker Glu-Val-Cit, a PBAC group and a cytotoxin MMAF (HY-15579). TCO-PEG3-Glu-Val-Cit-PABC-MMAF can be used for synthesis of dual drug ADC.
    TCO-PEG3-Glu-Val-Cit-PABC-MMAF
Drug-Linker Conjugates for ADC Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.